Rachelle Suzanne Jacques - Jan 1, 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Chief Executive Officer, Director
Signature
/s/ Rachelle Jacques
Stock symbol
AKTX
Transactions as of
Jan 1, 2024
Transactions value $
$0
Form type
3
Date filed
1/2/2024, 08:06 PM
Previous filing
Jun 20, 2023
Next filing
Apr 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX Ordinary Shares, par value $0.0001 per share 538M Jan 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 208M $0.01 Direct F2
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 29.8M $0.01 Direct F2
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 153M $0.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Securities beneficially owned totaling 538,457,900 includes 153,397,775 ordinary shares, par value $0.0001per share ("Ordinary Shares") owned and 385,060,125 of unvested time-based restricted stock units held by the Reporting Person.
F2 The stock option award was granted under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on March 28, 2022, subject to continued service with the Issuer.
F3 The stock option award was granted under the Issuer's 2014 Plan. The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on June 1, 2023, subject to continued service with the Issuer.